Do analysts prefer EMBC or AVNS?

Embecta currently has a consensus target price of $11.00, suggesting a potential upside of 115.69%. Given Embecta's stronger consensus rating and higher probable upside, analysts clearly believe Embecta is more favorable than Avanos Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Embecta 2 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.60 Avanos Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has stronger valuation and earnings, EMBC or AVNS?

Embecta has higher revenue and earnings than Avanos Medical. Avanos Medical is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Embecta $1.08B 0.27 $95.40M $1.48 3.45 Avanos Medical $715.90M 1.64 -$72.90M -$1.61 N/A

Is EMBC or AVNS more profitable?

Embecta has a net margin of 8.59% compared to Avanos Medical's net margin of -10.39%. Avanos Medical's return on equity of 5.39% beat Embecta's return on equity. Company Net Margins Return on Equity Return on Assets Embecta 8.59% -19.25% 10.82% Avanos Medical -10.39% 5.39% 3.97%

Does the media prefer EMBC or AVNS?

In the previous week, Embecta had 44 more articles in the media than Avanos Medical. MarketBeat recorded 46 mentions for Embecta and 2 mentions for Avanos Medical. Avanos Medical's average media sentiment score of 1.16 beat Embecta's score of 0.32 indicating that Avanos Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Embecta 4 Very Positive mention(s) 1 Positive mention(s) 34 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Avanos Medical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is QDEL or EMBC more profitable?

Embecta has a net margin of 8.59% compared to QuidelOrtho's net margin of -39.20%. QuidelOrtho's return on equity of 4.88% beat Embecta's return on equity. Company Net Margins Return on Equity Return on Assets QuidelOrtho -39.20% 4.88% 1.63% Embecta 8.59% -19.25% 10.82%

Does the media favor QDEL or EMBC?

In the previous week, Embecta had 38 more articles in the media than QuidelOrtho. MarketBeat recorded 46 mentions for Embecta and 8 mentions for QuidelOrtho. QuidelOrtho's average media sentiment score of 0.56 beat Embecta's score of 0.32 indicating that QuidelOrtho is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment QuidelOrtho 0 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Embecta 4 Very Positive mention(s) 1 Positive mention(s) 34 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, CERS or EMBC?

Embecta has higher revenue and earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cerus $206.13M 2.91 -$15.63M -$0.03 N/A Embecta $1.08B 0.27 $95.40M $1.48 3.45

Is CERS or EMBC more profitable?

Embecta has a net margin of 8.59% compared to Cerus' net margin of -3.06%. Cerus' return on equity of -10.19% beat Embecta's return on equity. Company Net Margins Return on Equity Return on Assets Cerus -3.06% -10.19% -3.14% Embecta 8.59% -19.25% 10.82%

Does the media favor CERS or EMBC?

In the previous week, Embecta had 43 more articles in the media than Cerus. MarketBeat recorded 46 mentions for Embecta and 3 mentions for Cerus. Cerus' average media sentiment score of 1.19 beat Embecta's score of 0.32 indicating that Cerus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cerus 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Embecta 4 Very Positive mention(s) 1 Positive mention(s) 34 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher earnings & valuation, EMBC or SMTI?

Embecta has higher revenue and earnings than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Embecta $1.08B 0.27 $95.40M $1.48 3.45 Sanara MedTech $103.12M 3.04 -$37.56M -$3.77 N/A

Is EMBC or SMTI more profitable?

Embecta has a net margin of 8.59% compared to Sanara MedTech's net margin of -29.15%. Sanara MedTech's return on equity of 29.72% beat Embecta's return on equity. Company Net Margins Return on Equity Return on Assets Embecta 8.59% -19.25% 10.82% Sanara MedTech -29.15% 29.72% 2.84%

Does the media refer more to EMBC or SMTI?

In the previous week, Embecta had 37 more articles in the media than Sanara MedTech. MarketBeat recorded 46 mentions for Embecta and 9 mentions for Sanara MedTech. Embecta's average media sentiment score of 0.32 beat Sanara MedTech's score of 0.23 indicating that Embecta is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Embecta 4 Very Positive mention(s) 1 Positive mention(s) 34 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Sanara MedTech 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher earnings & valuation, EMBC or RXST?

Embecta has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Embecta $1.08B 0.27 $95.40M $1.48 3.45 RxSight $134.48M 2.13 -$38.94M -$1.13 N/A

Is EMBC or RXST more profitable?

Embecta has a net margin of 8.59% compared to RxSight's net margin of -36.80%. RxSight's return on equity of -17.35% beat Embecta's return on equity. Company Net Margins Return on Equity Return on Assets Embecta 8.59% -19.25% 10.82% RxSight -36.80% -17.35% -14.70%

Does the media refer more to EMBC or RXST?

In the previous week, Embecta had 35 more articles in the media than RxSight. MarketBeat recorded 46 mentions for Embecta and 11 mentions for RxSight. Embecta's average media sentiment score of 0.32 beat RxSight's score of 0.15 indicating that Embecta is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Embecta 4 Very Positive mention(s) 1 Positive mention(s) 34 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral RxSight 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Embecta (EMBC) Competitors

$5.10 -0.01 (-0.20%)

Closing price 04:00 PM Eastern

Extended Trading

$5.06 -0.04 (-0.86%)

As of 07:49 PM Eastern

Compare

EMBC vs. AVNS, QDEL, CERS, SMTI, and RXST

Should you buy Embecta stock or one of its competitors? Embecta's main competitors and comparable companies include Avanos Medical (AVNS), QuidelOrtho (QDEL), Cerus (CERS), Sanara MedTech (SMTI), and RxSight (RXST). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare supplies" industry.

How does Embecta compare to Avanos Medical?

Embecta (NASDAQ:EMBC) and Avanos Medical (NYSE:AVNS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

Embecta has a net margin of 8.59% compared to Avanos Medical's net margin of -10.39%. Avanos Medical's return on equity of 5.39% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Embecta	8.59%	-19.25%	10.82%
Avanos Medical	-10.39%	5.39%	3.97%

Embecta currently has a consensus target price of $11.00, suggesting a potential upside of 115.69%. Given Embecta's stronger consensus rating and higher probable upside, analysts clearly believe Embecta is more favorable than Avanos Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60
Avanos Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Embecta had 44 more articles in the media than Avanos Medical. MarketBeat recorded 46 mentions for Embecta and 2 mentions for Avanos Medical. Avanos Medical's average media sentiment score of 1.16 beat Embecta's score of 0.32 indicating that Avanos Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Embecta	4 Very Positive mention(s)	1 Positive mention(s)	34 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Avanos Medical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Embecta has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market. Comparatively, Avanos Medical has a beta of 1.57, meaning that its share price is 57% more volatile than the broader market.

93.8% of Embecta shares are owned by institutional investors. Comparatively, 95.2% of Avanos Medical shares are owned by institutional investors. 1.3% of Embecta shares are owned by company insiders. Comparatively, 2.3% of Avanos Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Embecta has higher revenue and earnings than Avanos Medical. Avanos Medical is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.08B	0.27	$95.40M	$1.48	3.45
Avanos Medical	$715.90M	1.64	-$72.90M	-$1.61	N/A

Summary

Embecta beats Avanos Medical on 9 of the 15 factors compared between the two stocks.

How does Embecta compare to QuidelOrtho?

QuidelOrtho (NASDAQ:QDEL) and Embecta (NASDAQ:EMBC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

QuidelOrtho has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market. Comparatively, Embecta has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market.

Embecta has a net margin of 8.59% compared to QuidelOrtho's net margin of -39.20%. QuidelOrtho's return on equity of 4.88% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
QuidelOrtho	-39.20%	4.88%	1.63%
Embecta	8.59%	-19.25%	10.82%

In the previous week, Embecta had 38 more articles in the media than QuidelOrtho. MarketBeat recorded 46 mentions for Embecta and 8 mentions for QuidelOrtho. QuidelOrtho's average media sentiment score of 0.56 beat Embecta's score of 0.32 indicating that QuidelOrtho is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
QuidelOrtho	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Embecta	4 Very Positive mention(s)	1 Positive mention(s)	34 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

99.0% of QuidelOrtho shares are held by institutional investors. Comparatively, 93.8% of Embecta shares are held by institutional investors. 1.1% of QuidelOrtho shares are held by insiders. Comparatively, 1.3% of Embecta shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Embecta has lower revenue, but higher earnings than QuidelOrtho. QuidelOrtho is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
QuidelOrtho	$2.73B	0.36	-$1.13B	-$15.41	N/A
Embecta	$1.08B	0.27	$95.40M	$1.48	3.45

QuidelOrtho currently has a consensus target price of $13.63, suggesting a potential downside of 4.72%. Embecta has a consensus target price of $11.00, suggesting a potential upside of 115.69%. Given Embecta's stronger consensus rating and higher possible upside, analysts clearly believe Embecta is more favorable than QuidelOrtho.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
QuidelOrtho	3 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Embecta	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60

Summary

Embecta beats QuidelOrtho on 10 of the 15 factors compared between the two stocks.

How does Embecta compare to Cerus?

Cerus (NASDAQ:CERS) and Embecta (NASDAQ:EMBC) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

Cerus has a beta of 1.81, meaning that its share price is 81% more volatile than the broader market. Comparatively, Embecta has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market.

Embecta has a net margin of 8.59% compared to Cerus' net margin of -3.06%. Cerus' return on equity of -10.19% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cerus	-3.06%	-10.19%	-3.14%
Embecta	8.59%	-19.25%	10.82%

In the previous week, Embecta had 43 more articles in the media than Cerus. MarketBeat recorded 46 mentions for Embecta and 3 mentions for Cerus. Cerus' average media sentiment score of 1.19 beat Embecta's score of 0.32 indicating that Cerus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cerus	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Embecta	4 Very Positive mention(s)	1 Positive mention(s)	34 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Cerus presently has a consensus price target of $4.00, suggesting a potential upside of 34.23%. Embecta has a consensus price target of $11.00, suggesting a potential upside of 115.69%. Given Embecta's higher probable upside, analysts plainly believe Embecta is more favorable than Cerus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cerus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Embecta	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60

Embecta has higher revenue and earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerus	$206.13M	2.91	-$15.63M	-$0.03	N/A
Embecta	$1.08B	0.27	$95.40M	$1.48	3.45

78.4% of Cerus shares are held by institutional investors. Comparatively, 93.8% of Embecta shares are held by institutional investors. 5.3% of Cerus shares are held by company insiders. Comparatively, 1.3% of Embecta shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Embecta beats Cerus on 9 of the 16 factors compared between the two stocks.

How does Embecta compare to Sanara MedTech?

Embecta (NASDAQ:EMBC) and Sanara MedTech (NASDAQ:SMTI) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

Embecta has higher revenue and earnings than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.08B	0.27	$95.40M	$1.48	3.45
Sanara MedTech	$103.12M	3.04	-$37.56M	-$3.77	N/A

93.8% of Embecta shares are owned by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are owned by institutional investors. 1.3% of Embecta shares are owned by company insiders. Comparatively, 42.0% of Sanara MedTech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Embecta has a net margin of 8.59% compared to Sanara MedTech's net margin of -29.15%. Sanara MedTech's return on equity of 29.72% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Embecta	8.59%	-19.25%	10.82%
Sanara MedTech	-29.15%	29.72%	2.84%

In the previous week, Embecta had 37 more articles in the media than Sanara MedTech. MarketBeat recorded 46 mentions for Embecta and 9 mentions for Sanara MedTech. Embecta's average media sentiment score of 0.32 beat Sanara MedTech's score of 0.23 indicating that Embecta is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Embecta	4 Very Positive mention(s)	1 Positive mention(s)	34 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Sanara MedTech	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Embecta presently has a consensus target price of $11.00, indicating a potential upside of 115.69%. Sanara MedTech has a consensus target price of $35.00, indicating a potential upside of 2.49%. Given Embecta's higher possible upside, equities analysts plainly believe Embecta is more favorable than Sanara MedTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60
Sanara MedTech	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Embecta has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market.

Summary

Embecta beats Sanara MedTech on 10 of the 15 factors compared between the two stocks.

How does Embecta compare to RxSight?

Embecta (NASDAQ:EMBC) and RxSight (NASDAQ:RXST) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

93.8% of Embecta shares are owned by institutional investors. Comparatively, 78.8% of RxSight shares are owned by institutional investors. 1.3% of Embecta shares are owned by company insiders. Comparatively, 10.1% of RxSight shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Embecta has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market. Comparatively, RxSight has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market.

In the previous week, Embecta had 35 more articles in the media than RxSight. MarketBeat recorded 46 mentions for Embecta and 11 mentions for RxSight. Embecta's average media sentiment score of 0.32 beat RxSight's score of 0.15 indicating that Embecta is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Embecta	4 Very Positive mention(s)	1 Positive mention(s)	34 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
RxSight	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Embecta has a net margin of 8.59% compared to RxSight's net margin of -36.80%. RxSight's return on equity of -17.35% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Embecta	8.59%	-19.25%	10.82%
RxSight	-36.80%	-17.35%	-14.70%

Embecta has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.08B	0.27	$95.40M	$1.48	3.45
RxSight	$134.48M	2.13	-$38.94M	-$1.13	N/A

Embecta presently has a consensus target price of $11.00, indicating a potential upside of 115.69%. RxSight has a consensus target price of $8.37, indicating a potential upside of 21.43%. Given Embecta's higher possible upside, equities analysts plainly believe Embecta is more favorable than RxSight.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92

Summary

Embecta beats RxSight on 10 of the 16 factors compared between the two stocks.

Get Embecta News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EMBC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EMBC vs. The Competition

Export

Metric	Embecta	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$289.53M	$5.95B	$7.06B	$13.10B
Dividend Yield	0.78%	1.76%	2.57%	10.45%
P/E Ratio	3.45	26.22	269.06	25.28
Price / Sales	0.27	63.09	602.43	91.76
Price / Cash	1.28	33.92	70.48	50.90
Price / Book	-0.47	6.10	12.91	6.24
Net Income	$95.40M	$148.67M	$3.45B	$347.60M
7 Day Performance	15.38%	1.84%	1.12%	1.07%
1 Month Performance	64.52%	4.56%	1.79%	1.03%
1 Year Performance	-63.23%	8.67%	67.69%	20.77%

Embecta Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EMBC Embecta	3.8665 of 5 stars	$5.10 -0.2%	$11.00 +115.7%	-63.3%	$289.53M	$1.08B	3.45	1,850	Trending News Earnings Report Insider Trade
AVNS Avanos Medical	1.3062 of 5 stars	$24.99 flat	N/A	N/A	$1.17B	$715.90M	N/A	2,287	Positive News
QDEL QuidelOrtho	1.5154 of 5 stars	$13.63 -0.9%	$13.63	-44.3%	$928.68M	$2.73B	N/A	6,500	Analyst Downgrade
CERS Cerus	2.1128 of 5 stars	$2.58 +2.2%	$4.00 +55.3%	+113.5%	$518.91M	$206.13M	N/A	290	Positive News
SMTI Sanara MedTech	1.5817 of 5 stars	$34.21 -0.1%	$35.00 +2.3%	+7.0%	$313.42M	$103.12M	N/A	60	Earnings Report Analyst Upgrade Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EMBC) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Embecta (EMBC) Competitors

EMBC vs. AVNS, QDEL, CERS, SMTI, and RXST

How does Embecta compare to Avanos Medical?

Summary

How does Embecta compare to QuidelOrtho?

Summary

How does Embecta compare to Cerus?

Summary

How does Embecta compare to Sanara MedTech?

Summary

How does Embecta compare to RxSight?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EMBC vs. The Competition

Embecta Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Embecta (EMBC) Competitors

EMBC vs. AVNS, QDEL, CERS, SMTI, and RXST

How does Embecta compare to Avanos Medical?

Is EMBC or AVNS more profitable?

Do analysts prefer EMBC or AVNS?

Does the media prefer EMBC or AVNS?

Which has more risk & volatility, EMBC or AVNS?

Do insiders & institutionals hold more shares of EMBC or AVNS?

Which has stronger valuation and earnings, EMBC or AVNS?

Summary

How does Embecta compare to QuidelOrtho?

Which has more volatility and risk, QDEL or EMBC?

Is QDEL or EMBC more profitable?

Does the media favor QDEL or EMBC?

Do institutionals & insiders hold more shares of QDEL or EMBC?

Which has higher valuation & earnings, QDEL or EMBC?

Do analysts prefer QDEL or EMBC?

Summary

How does Embecta compare to Cerus?

Which has more risk & volatility, CERS or EMBC?

Is CERS or EMBC more profitable?

Does the media favor CERS or EMBC?

Do analysts prefer CERS or EMBC?

Which has preferable valuation and earnings, CERS or EMBC?

Do insiders & institutionals believe in CERS or EMBC?

Summary

How does Embecta compare to Sanara MedTech?

Which has higher earnings & valuation, EMBC or SMTI?

Do institutionals and insiders believe in EMBC or SMTI?

Is EMBC or SMTI more profitable?

Does the media refer more to EMBC or SMTI?

Do analysts prefer EMBC or SMTI?

Which has more volatility & risk, EMBC or SMTI?

Summary

How does Embecta compare to RxSight?

Do institutionals and insiders believe in EMBC or RXST?

Which has more volatility & risk, EMBC or RXST?

Does the media refer more to EMBC or RXST?

Is EMBC or RXST more profitable?

Which has higher earnings & valuation, EMBC or RXST?

Do analysts prefer EMBC or RXST?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EMBC vs. The Competition

Embecta Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools